-
Nanoform successfully completes new share issue raising EUR 25 million to prepare for GMP manufacturing in the USA
-
-
Global experts in nanotechnology and drug particle engineering
Our latest videos
Press releases
-
Regulatory September 7, 2022Nanoform Finland Plc – Manager’s transactions – Niklas Sandler
-
Regulatory September 6, 2022Share subscriptions based on Nanoform Finland Plc’s stock options 2-3/2019 and 1/2020
-
Regulatory August 25, 2022Nanoform Q2 and H1 2022 report: Strong momentum continues
Nanoform published its Interim Report January-June 2022 on August 25th, 2022, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time.
a
About Nanoform
Our work enables our partners to overcome drug development challenges to rapidly progress novel drugs to market. We are driven by a passion for innovation, and constantly work to find ground-breaking solutions that enhance drug effectiveness and targeting.
Expert services
Our nanoforming services provide solutions to complex formulation challenges by increasing drug solubility and bioavailability. The advanced production of nanoparticles provides pharmacokinetic improvements, commercial opportunities and novel avenues for drug delivery.
Team
We have established a multidisciplinary team that brings together world-class scientists with experts in pharmaceutical business development. Every member of the team is committed to the enhancement of drug compounds for swift progression to the market.
Working together for enhanced drug development
Our nanoforming technologies and services span the full range of drug development from small-molecule nanoparticles to large-molecule biologics. We support all phases of drug development, accelerating your time to clinic for GMP manufacture while also increasing possibilities and probabilities of success in taking your product to market.
Nanoform’s platform is exciting for its broad applicability to drug development across all therapeutic areas
